Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Adequate bone marrow function
eGFR ≥ 30 mL/min
Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
Serum calcium (corrected for albumin) at or below the ULN range
Candidate for treatment regimens known to provide clinical benefit in MM
Active infection requiring parenteral anti-infective treatment
Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety